



**SOLVE**  
**ON.**

## **Incyte Announces Inaugural Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the Vitiligo Community**

- *American Academy of Dermatology and VStrong Vitiligo Support Community selected to receive awards up to \$100,000 and \$35,000 respectively*
- *Incyte Ingenuity Awards in vitiligo now accepting applications for the next awards cycle; interested applicants have until October 31, 2023 to apply*

**WILMINGTON, Del. – June 25, 2023** – Today, Incyte announced that the American Academy of Dermatology (AAD) and VStrong Vitiligo Support Community have been chosen as the first recipients of the Incyte Ingenuity Awards in vitiligo. This annual award, which debuted in 2022, aims to support the vitiligo community by funding two novel initiatives, one up to \$35,000 and another up to \$100,000, that address specific needs of people with vitiligo. Applications for the Ingenuity Awards are reviewed and evaluated by a judging panel consisting of vitiligo experts and advocates.

AAD was selected to receive an award up to \$100,000 for its project, *Good Skin Knowledge*. This project aims to destigmatize vitiligo and increase awareness of the condition by equipping educators and community leaders with English and Spanish training modules that teach children about vitiligo. The goal of the modules is to ease the burden of the condition by educating children about vitiligo and how it affects people living with the condition, encouraging compassion and awareness.

VStrong Vitiligo Support Community was selected to receive an award up to \$35,000 for its project, *VStrong “Shine” – Vitiligo Sun Protection Strategy*. In partnership with the Henry Ford Hospital Dermatology Department, this project aims to leverage knowledge from various stakeholders to develop resources for the vitiligo community about safe sun exposure and self-care tips for sunburn relief. Through an interactive workshop, the vitiligo community will be provided with the necessary tools, education and resources to protect themselves from unsafe exposure to the sun while addressing the feelings associated with the visual stigma of vitiligo.

“The Incyte Ingenuity Awards in vitiligo were created to support the vitiligo community and bring to life their innovative ideas to address unmet needs for people living with this condition,” said Todd Edwards, Group Vice President, Inflammation and Autoimmunity, Incyte. “We are proud to support AAD and VStrong Vitiligo Support Community in their pursuit to assist the vitiligo community with their initiatives and look forward to seeing their progress throughout the next year.”

The judging panel is comprised of the following vitiligo experts and advocates: Erika Page, Founder and Editor, *Living Dappled*; Vivian Shi, Associate Professor, Department of Dermatology, University of Arkansas for Medical Sciences; Gwen Dalphon, board-certified Physician Assistant; James McLeod, Vitiligo advocate; and Heather Woolery-Lloyd, MD, Director of the Skin of Color Division for the University of Miami Department of Dermatology and Cutaneous Surgery.

Incyte also announced the opening of the next application cycle for the Incyte Ingenuity Awards in vitiligo aimed at funding thoughtful, creative and original programs and resources that address specific needs of people with vitiligo. This year brings a new, streamlined application process which starts with a letter of intent, followed by a more detailed application form in round two. Submissions can be made by non-profit 501(c)(3), patient, policy and caregiver organizations or healthcare providers and mid-level/junior faculty from healthcare organizations. All letters of intent must be submitted by October 31, 2023 and the recipients will be announced in 2024.

To learn more about the winning initiatives, eligibility criteria and how to submit an application for the Incyte Ingenuity Awards in vitiligo program, visit <https://www.incyteingenuityawards.com/vitiligo>.

### **About Vitiligo**

Vitiligo is a chronic autoimmune condition characterized by depigmentation (loss of color) of skin that results from the loss of pigment-producing cells known as melanocytes. In the United States, more than 1.5 million people are diagnosed with vitiligo<sup>1</sup>. The overall prevalence of the condition is estimated at approximately 2-3 million<sup>2</sup>, with the majority of people with vitiligo (approximately 85%) having nonsegmental vitiligo<sup>3</sup>. Often misperceived as a cosmetic condition, vitiligo can have a profound impact on people's lives<sup>4</sup>.

### **About Incyte Dermatology**

Incyte's science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are engaging research and development in number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, lichen planus, lichen sclerosus and prurigo nodularis.

To learn more, visit the [Dermatology section](#) of [Incyte.com](#).

### **About Incyte**

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](#) and follow [@Incyte](#).

###

#### **Contact:**

Jenifer Antonacci  
Executive Director, Public Affairs  
Tel: +1 302 498 7036  
[jantonacci@incyte.com](mailto:jantonacci@incyte.com)

---

<sup>1</sup> Bergqvist C, Ezzedine K. Vitiligo: A Review. *Dermatology* 2020;236:571-592.

<sup>2</sup> Gandhi K, et al. Prevalence of vitiligo among adults in the United States. *JAMA Dermatol.* 2022;158(1):43-50.

<sup>3</sup> Ezzedine K, et al. Seminar: Vitiligo. *Lancet* 2015;386:74-84.

<sup>4</sup> Bowcock A, et al. Targeting skin: vitiligo and autoimmunity. *J Invest Dermatol.* 2012;132(1):13-15.